

INFORMATION DISCLOSURE STATEMENT LIST (Use as many sheets as necessary)				Complete if Known			
				Application Number	10/505,244		
				Filing Date	January 18, 2005		
				First Named Inventor	Kuwada		
				Group Art Unit	1628		
				Examiner Name	Pagonakis, Anna		
U.S. PATENT DOCUMENTS							
Examiner's Initials	Cite No.	Document No.	Date	Name	Class	Subclass	Filing Date (if appropriate)
FOREIGN PATENT DOCUMENTS							
Examiner's Initials	Cite No.	Foreign Patent Document Country Code-Number-Kind Code	Date	Name	Translation Yes/No		
NON-PATENT DOCUMENTS							
Examiner's Initials	Cite No.	Non-Patent Citations (include Author, Title, Publisher, Relevant Pages, Date and Place of Publication)					
	D1	Canadian Intellectual Property Office, Official Action issued in Canadian Application No. 2,477,172 on November 3, 2009.					
	D2	Ghanim et al., Supression of nuclear factor-kappaB and stimulation of inhibitor kappaB by troglitazone:evidence for an anti-inflammatory effect and potential antiatherosclerotic effect in the obese," J. Clin. Endocrinol. Metab., 86(3):1306-12, 2001.					
	D3	Hazzalin et al., "Anisomycin selectively desensitizes signaling components involved in stress kinase activation and fos and jun induction," Mol. Cell. Biol., 18(4):1844-54, 1998.					
	D4	International Search Authority, International Search Report and Written Opinion for PCT/US2009/039508 mailed September 24, 2009					
	D5	Scaife <i>et al.</i> , "Nuclear Factor B Inhibitors Induce Adhesion-dependent Colon Cancer Apoptosis: Implications for Metastasis," <i>Cancer Res.</i> 62:6870-6878, December 1, 2002.					
Examiner Signature:				Date Considered:			
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							